BREHAB: Prehabilitation and Rehabilitation in Breast Cancer Surgery Patients - a Pilot Study

Sponsor
Franciscus Gasthuis (Other)
Overall Status
Recruiting
CT.gov ID
NCT06076616
Collaborator
(none)
40
1
2
13
3.1

Study Details

Study Description

Brief Summary

Prehabilitation and rehabilitation through personalized lifestyle counseling in patients with breast cancer.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Prehabilitation and rehabilitation
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
A pilot studyA pilot study
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Prehabilitation and Rehabilitation in Breast Cancer Surgery Patients - a Pilot Study
Actual Study Start Date :
Dec 1, 2022
Anticipated Primary Completion Date :
Dec 1, 2023
Anticipated Study Completion Date :
Jan 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Prehabilitation/rehabilitation

Patients in this arm follow a lifestyle counseling programme starting from diagnosis up to 6 months postoperatively.

Behavioral: Prehabilitation and rehabilitation
A personalized lifestyle counseling programme.

No Intervention: Usual care

Patients in this arm follow usual care.

Outcome Measures

Primary Outcome Measures

  1. Recruitment/consent rate [From baseline to 6 months postoperatively]

    To estimate patient recruitment/consent rate to the prehabilitation/rehabilitation group Enrolment logs will be recorded for all patients who meet the eligibility criteria. Reasons for non-participation will be recorded. We define a success criterion of 40% of the total number of participants invited to be recruited to the pilot study.

  2. Attendance rate [From baseline to 6 months postoperatively]

    To estimate patient attendance, measured by the number of sessions attended out of 10. Reasons for non-attendance will be collected and withdrawals tracked. We will consider an attendance rate of 80% satisfactory

  3. Patient adherence [From baseline to 6 months postoperatively]

    To estimate patient adherence monitored with the aid of the wearables. Adherence is defined as at least 150 min of moderate intensity exercise and at least two strength training sessions per week. Exercise instructions are based on the Health Council's exercise guidelines. We will consider an adherence of 70% as satisfactory.

  4. Withdrawals [From baseline to 6 months postoperatively]

    To estimate the number of withdrawals, defined as the proportion of patients who quit the intervention before reaching the primary endpoint (HRQOL at six months after surgery). Information about the reasons for withdrawal will be collected.

  5. Patient satisfaction [From baseline to 6 months postoperatively]

    To estimate patient satisfaction with the programme assessed during three interviews: at four weeks, at three months after surgery and at the end of the study. Satisfaction is defined as: satisfaction with the lifestyle coach, satisfaction with the duration of the intervention, satisfaction with the physical training programme. Patients will be given room for their own input to improve the intervention.

  6. Selection bias [From baseline to 6 months postoperatively]

    To explore any evidence of selection bias in participants recruited into the study (assessed through participant characteristics at baseline).

Secondary Outcome Measures

  1. Likely changes in Health Related Quality of Life (HRQOL) [Baseline, the day before surgery, 6 months postoperatively]

    To investigate likely changes in the primary outcome measure HRQOL measured with the EORTC-QLQ-30 questionnaire at six months after surgery.

  2. Likely changes in BMI [Baseline, the day before surgery, 6 months postoperatively]

    Body Mass Index

  3. Likely changes in functional capacity (physical fitness) [Baseline, the day before surgery, 6 months postoperatively]

    Measured using the 6 minute walking test (6MWT)

  4. Likely changes in the number of postoperative complications [30 days after surgery]

    Complications within 30 days after surgery, measured with the Comprehensive Complication Index (CCI)

  5. Likely changes in smoking status [Measured at baseline and 6 months postoperatively]

    Smoking status (yes/no) as assessed by the primary investigator

  6. Likely changes in postoperative functional recovery [The day after surgery]

    Measured the day after surgery with the MILAS and DEMMI questionnaires

  7. Likely changes in mean score of the different BREAST-Q scales [The questionnaire will be administered at enrolment and at six months after surgery.]

    Measured using the BREAST-Q questionnaire

  8. Likely changes in mean score of quality of life by means of the EORTC-BR23 questionnaire [The questionnaire will be administered at enrolment and at six months after surgery.]

    Measured using the EORTC-BR23 questionnaire

  9. Likely changes in mean score of the different EORTC-QLQ-30 scales which will be administered at enrolment and six months after surgery. [The questionnaire will be administered at enrolment and at six months after surgery.]

    Measured using the EORTC-QLQ-30 questionnaire

  10. Likely changes in mean score of the EQ5D-5L questionnaire [The questionnaire will be administered at enrolment and at six months after surgery.]

    Measured using the EQ-5D-5L questionnaire

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No

Inclusion criteria

  1. Woman with a confirmed breast cancer diagnosis

  2. Planned surgical treatment of breast cancer

  3. Age 18 years or older

  4. Provision of written informed consent

Exclusion criteria

  1. Severe mental retardation, which limits the ability to follow instructions independently

  2. Severe psychiatric problems, which limits the ability to follow instructions independently

  3. Legal incapacity

  4. Language barrier: If we cannot find a lifestyle coach who speaks the patient's language, unfortunately we cannot offer the lifestyle coaching in its entirety, and this option will be omitted for the patient.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Franciscus Gasthuis en Vlietland Rotterdam Zuid-Holland Netherlands 3045PM

Sponsors and Collaborators

  • Franciscus Gasthuis

Investigators

  • Principal Investigator: Taco Klem, MD,PHD, Franciscus Gasthuis & Vlietland

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Franciscus Gasthuis
ClinicalTrials.gov Identifier:
NCT06076616
Other Study ID Numbers:
  • 2022-097
First Posted:
Oct 11, 2023
Last Update Posted:
Oct 11, 2023
Last Verified:
Nov 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 11, 2023